Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update.

ABSTRACT: Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder with substantial socioeconomic impact, characterized by the gradual loss of dopaminergic neurons, dopamine deficiency, and pathological processes such as neuroinflammation, oxidative stress, and α-synuclein aggregation. Monoamine oxidases (MAOs) are enzymes responsible for the degradation of neuroactive amines, including dopamine, a neurotransmitter essential for motor, cognitive, and behavioral functions. Among these, MAO-B plays a central role in dopamine metabolism, producing reactive metabolites and oxidative species that contribute to the oxidative stress associated with PD pathophysiology. In this context, MAO-B inhibition has emerged as a promising therapeutic strategy. However, specific limitati

SUBMITTER: Ribeiro LV 

PROVIDER: S-EPMC12567508 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature